Home/Pipeline/CT-152 (Rejoyn™)

CT-152 (Rejoyn™)

Major Depressive Disorder (adjunct to antidepressant medication)

Phase 3FDA-cleared

Key Facts

Indication
Major Depressive Disorder (adjunct to antidepressant medication)
Phase
Phase 3
Status
FDA-cleared
Company

About Click Therapeutics

Click Therapeutics is redefining modern medicine by developing patient-centric digital treatments delivered via smartphone and prescribed by physicians. The company leverages a multimodal, platform-based approach that combines scientifically proven therapies with proprietary neuromodulatory mechanisms to drive clinically meaningful outcomes. With an FDA-cleared product for depression and multiple Phase 3 programs in neurology and psychiatry, Click is positioned at the forefront of the rapidly evolving digital therapeutics market. Their innovative Software-Enhanced Drugs™ platform represents a novel approach to enhancing traditional pharmacotherapy through digital interventions.

View full company profile